| 255.56 2.28 (0.9%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 308.06 | 1-year : | 321.46 |
| Resists | First : | 263.75 | Second : | 275.23 |
| Pivot price | 258.54  |
|||
| Supports | First : | 245.19 | Second : | 203.99 |
| MAs | MA(5) : | 255.01 |
MA(20) : | 261.39 |
| MA(100) : | 255.43 |
MA(250) : | 233 |
|
| MACD | MACD : | -3.4 |
Signal : | -2.6 |
| %K %D | K(14,3) : | 31.1 |
D(3) : | 28.3 |
| RSI | RSI(14): 43.8 |
|||
| 52-week | High : | 281.07 | Low : | 180.59 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ JNJ ] has closed above bottom band by 37.7%. Bollinger Bands are 11.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 257.79 - 259.04 | 259.04 - 260.12 |
| Low: | 250.99 - 252.44 | 252.44 - 253.7 |
| Close: | 253.4 - 255.64 | 255.64 - 257.57 |
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Fri, 16 Oct 2026
Chicago mayoral election 2027: Brandon Johnson trails Alexi Giannoulias, John Kelly, Susana Mendoza, Joe Holberg in fundraising - ABC7 Chicago
Fri, 16 Oct 2026
Top-20 prospect Jamarcus Johnson previews Miami, sets three more key visits - 247Sports
Fri, 16 Oct 2026
Why Eddie Johnson is inflaming feud with ex-USMNT teammate Landon Donovan - The New York Times
Fri, 16 Oct 2026
MGK spends the night at Dakota Johnson’s house after wrapping up studio session in LA - Page Six
Fri, 16 Oct 2026
Johnson County man sentenced to 19 years in prison for $1 billion Medicare fraud scheme - Johnson County Post
Thu, 15 Oct 2026
Dakota Johnson & MGK Fuel More Romance Rumors During Night Out in L.A. - Just Jared
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,410 (M) |
| Shares Float | 2,410 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 76.7 (%) |
| Shares Short | 22,070 (K) |
| Shares Short P.Month | 21,670 (K) |
| EPS | 8.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 35.27 |
| Profit Margin | 21.4 % |
| Operating Margin | 29.1 % |
| Return on Assets (ttm) | 8.6 % |
| Return on Equity (ttm) | 25.7 % |
| Qtrly Rev. Growth | 6.5 % |
| Gross Profit (p.s.) | 27.68 |
| Sales Per Share | 40.63 |
| EBITDA (p.s.) | 14.46 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 27,610 (M) |
| Levered Free Cash Flow | 16,890 (M) |
| PE Ratio | 29.61 |
| PEG Ratio | 2.6 |
| Price to Book value | 7.24 |
| Price to Sales | 6.28 |
| Price to Cash Flow | 22.3 |
| Dividend | 1.34 |
| Forward Dividend | 0 |
| Dividend Yield | 0.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|